-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the market competitiveness of global biopharmaceuticals has been significantly enhanced
.
It is worth noting that, with the help of a series of policies, China's biopharmaceutical industry has also begun to enter a stage of vigorous development and continuous rise
.
Forecasts show that the global biopharmaceutical market space will reach 7680 billion U.
S.
dollars in 2030, of which China's biopharmaceutical market space will increase to 1,303 billion yuan, and China will account for 25% of the global biopharmaceutical market
.
At the same time, the proportion of China's biological medicine market will be on par with that of chemical medicines, accounting for 40%
.
The commercial production of biopharmaceuticals is facing many pain points (picture source: pharma.
com) In this context, it has become an industry consensus that China's biopharmaceuticals will usher in an era of large-scale manufacturing and mass production
.
But at the same time, the industry has also pointed out that the biopharmaceutical process is different from traditional pharmaceuticals, and many problems that need to be solved in the commercial production process are actually emerging
.
Among them, take the expansion and capacity expansion as an example.
In this process, the reactor in the upstream cell culture stage has requirements for engineering weighing and layer height, especially after the expansion of the fermentation scale, it is even more necessary.
It is supplemented with equipment of corresponding magnitude
.
In addition, in the production of downstream preparations, biological products are non-terminally sterilized products, and some fragile protein preparations need to meet conditions such as low-temperature filling production, so there will be certain special requirements for production links and equipment
.
From the above point of view, the commercial production process of biopharmaceuticals is actually inseparable from the assistance of pharmaceutical equipment
.
In this regard, the analysis believes that with the continuous expansion of China's biopharmaceutical market, the equipment companies required for the industrialization of biopharmaceuticals will also usher in benefits and gain more market opportunities
.
In fact, focusing on the future plans of the pharmaceutical equipment giants, the field of biopharmaceuticals has obviously become a sweet pastry
.
Take Chutian Technology as an example.
In a survey activity on September 15th, Chutian Technology revealed the company’s plan for biopharmaceutical-related fields, and made it clear that it will take heavy investment and major development in biopharmaceutical-related products.
The sales growth rate of biopharmaceutical-related process technology and process equipment exceeds that of other product lines
.
The company benchmarks Sartorius in the biological field, complementing related product series and industrial chain
.
In addition to Chutian Technology, Tofflon also revealed in previous institutional surveys that the preparation of biomedical solutions and the output of engineering capabilities will be the track for the rapid growth of the demand for innovative drugs in China and even the world in the future.
Tofflon will form a team to meet the needs of the domestic market.
Foreign market demand
.
In addition, Canaan Technology also plans to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems and pharmaceutical R&D services for innovative biological drugs
.
In general, the broad development prospects of the biopharmaceutical market have become the driving force for many industries and enterprises to enter it, and the same is true for the pharmaceutical equipment industry
.
Especially in the current stage of accelerated commercial production of biopharmaceuticals, the industry has generally believed that high-end biopharmaceutical equipment will become an indispensable pharmaceutical aid
.
However, it should be noted that the biopharmaceutical industry tends to have higher technological and technical requirements for related pharmaceutical equipment
.
Therefore, in order to achieve better results at the level of biopharmaceutical production and ensure the safety of R&D and production, domestic pharmaceutical machinery companies need to continue to increase investment in innovation and develop more high-quality, high-tech equipment while seeing opportunities.
, In order to better help China's biopharmaceutical industry to achieve commercial production, and help the entire industry to embark on a road of high-quality development
.
.
It is worth noting that, with the help of a series of policies, China's biopharmaceutical industry has also begun to enter a stage of vigorous development and continuous rise
.
Forecasts show that the global biopharmaceutical market space will reach 7680 billion U.
S.
dollars in 2030, of which China's biopharmaceutical market space will increase to 1,303 billion yuan, and China will account for 25% of the global biopharmaceutical market
.
At the same time, the proportion of China's biological medicine market will be on par with that of chemical medicines, accounting for 40%
.
The commercial production of biopharmaceuticals is facing many pain points (picture source: pharma.
com) In this context, it has become an industry consensus that China's biopharmaceuticals will usher in an era of large-scale manufacturing and mass production
.
But at the same time, the industry has also pointed out that the biopharmaceutical process is different from traditional pharmaceuticals, and many problems that need to be solved in the commercial production process are actually emerging
.
Among them, take the expansion and capacity expansion as an example.
In this process, the reactor in the upstream cell culture stage has requirements for engineering weighing and layer height, especially after the expansion of the fermentation scale, it is even more necessary.
It is supplemented with equipment of corresponding magnitude
.
In addition, in the production of downstream preparations, biological products are non-terminally sterilized products, and some fragile protein preparations need to meet conditions such as low-temperature filling production, so there will be certain special requirements for production links and equipment
.
From the above point of view, the commercial production process of biopharmaceuticals is actually inseparable from the assistance of pharmaceutical equipment
.
In this regard, the analysis believes that with the continuous expansion of China's biopharmaceutical market, the equipment companies required for the industrialization of biopharmaceuticals will also usher in benefits and gain more market opportunities
.
In fact, focusing on the future plans of the pharmaceutical equipment giants, the field of biopharmaceuticals has obviously become a sweet pastry
.
Take Chutian Technology as an example.
In a survey activity on September 15th, Chutian Technology revealed the company’s plan for biopharmaceutical-related fields, and made it clear that it will take heavy investment and major development in biopharmaceutical-related products.
The sales growth rate of biopharmaceutical-related process technology and process equipment exceeds that of other product lines
.
The company benchmarks Sartorius in the biological field, complementing related product series and industrial chain
.
In addition to Chutian Technology, Tofflon also revealed in previous institutional surveys that the preparation of biomedical solutions and the output of engineering capabilities will be the track for the rapid growth of the demand for innovative drugs in China and even the world in the future.
Tofflon will form a team to meet the needs of the domestic market.
Foreign market demand
.
In addition, Canaan Technology also plans to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems and pharmaceutical R&D services for innovative biological drugs
.
In general, the broad development prospects of the biopharmaceutical market have become the driving force for many industries and enterprises to enter it, and the same is true for the pharmaceutical equipment industry
.
Especially in the current stage of accelerated commercial production of biopharmaceuticals, the industry has generally believed that high-end biopharmaceutical equipment will become an indispensable pharmaceutical aid
.
However, it should be noted that the biopharmaceutical industry tends to have higher technological and technical requirements for related pharmaceutical equipment
.
Therefore, in order to achieve better results at the level of biopharmaceutical production and ensure the safety of R&D and production, domestic pharmaceutical machinery companies need to continue to increase investment in innovation and develop more high-quality, high-tech equipment while seeing opportunities.
, In order to better help China's biopharmaceutical industry to achieve commercial production, and help the entire industry to embark on a road of high-quality development
.
